AI Article Synopsis
- The ASXL1 gene is crucial for regulating gene expression and differentiation in blood cells, and its mutations are linked to severe blood disorders.
- Research using techniques to silence ASXL1 revealed that its absence impairs the formation of specific immune cell types (CD11b(+) and CD15(+)), indicating problems with granulomonocytic differentiation.
- Further analysis showed a significant dysregulation of gene expression and pathways in ASXL1-deficient cells, particularly affecting genes related to the PRC2 complex, which is important for gene repression and differentiation.
Article Abstract
The ASXL1 gene encodes a chromatin-binding protein involved in epigenetic regulation in haematopoietic cells. Loss-of-function ASXL1 mutations occur in patients with a range of myeloid malignancies and are associated with adverse outcome. We have used lentiviral-based shRNA technology to investigate the effects of ASXL1 silencing on cell proliferation, apoptosis, myeloid differentiation and global gene expression in human CD34(+) cells differentiated along the myeloid lineage in vitro. ASXL1-deficient cells showed a significant decrease in the generation of CD11b(+) and CD15(+) cells, implicating impaired granulomonocytic differentiation. Furthermore, colony-forming assays showed a significant increase in the number of multipotent mixed lineage colony-forming unit (CFU-GEMM) colonies and a significant decrease in the numbers of granulocyte-macrophage CFU (CFU-GM) and granulocyte CFU (CFU-G) colonies in ASXL1-deficient cells. Our data suggests that ASXL1 knockdown perturbs human granulomonocytic differentiation. Gene expression profiling identified many deregulated genes in the ASXL1-deficient cells differentiated along the granulomonocytic lineage, and pathway analysis showed that the most significantly deregulated pathway was the LXR/RXR activation pathway. ASXL1 may play a key role in recruiting the polycomb repressor complex 2 (PRC2) to specific loci, and we found over-representation of PRC2 targets among the deregulated genes in ASXL1-deficient cells. These findings shed light on the functional role of ASXL1 in human myeloid differentiation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.12217 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy.
Science
October 2024
Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Epigenetic reinforcement of T cell exhaustion is known to be a major barrier limiting T cell responses during immunotherapy. However, the core epigenetic regulators restricting antitumor immunity during prolonged antigen exposure are not clear. We investigated three commonly mutated epigenetic regulators that promote clonal hematopoiesis to determine whether they affect T cell stemness and response to checkpoint blockade immunotherapy.
View Article and Find Full Text PDFTargeting BIRC5 as a therapeutic approach to overcome ASXL1-associated decitabine resistance.
Cancer Lett
July 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China; Tianjin Institutes of Health Science, Tianjin, 301600, China. Electronic address:
Hypomethylating agents (HMAs) are widely employed in the treatment of myeloid malignancies. However, unresponsive or resistant to HMAs occurs in approximately 50 % of patients. ASXL1, one of the most commonly mutated genes across the full spectrum of myeloid malignancies, has been reported to predict a lower overall response rate to HMAs, suggesting an essential need to develop effective therapeutic strategies for the patients with HMA failure.
View Article and Find Full Text PDFAsxl1 exerts an antiproliferative effect on mouse lung maturation via epigenetic repression of the E2f1-Nmyc axis.
Cell Death Dis
November 2018
Department of Integrative Bioscience and Biotechnology, Sejong University, Seoul, 05006, Korea.
Although additional sex combs-like 1 (ASXL1) has been extensively described in hematologic malignancies, little is known about the molecular role of ASXL1 in organ development. Here, we show that Asxl1 ablation in mice results in postnatal lethality due to cyanosis, a respiratory failure. This lung defect is likely caused by higher proliferative potential and reduced expression of surfactant proteins, leading to reduced air space and defective lung maturation.
View Article and Find Full Text PDFASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1.
Blood Adv
October 2018
Department of Pathology and Immunology.
Additional sex comb-like 1 () mutations are commonly associated with myeloid malignancies and are markers of aggressive disease. The fact that ASXL1 is necessary for myeloid differentiation raises the possibility it also regulates osteoclasts. We find deletion of ASXL1 in myeloid cells results in bone loss with increased abundance of osteoclasts.
View Article and Find Full Text PDFAsxl1 deficiency in embryonic fibroblasts leads to cellular senescence via impairment of the AKT-E2F pathway and Ezh2 inactivation.
Sci Rep
July 2017
Department of Bioscience and Biotechnology, BK21 Graduate Program, Sejong University, 209 Neungdong-ro, Gwangjin-gu, Seoul, 143-747, Korea.
Although ASXL1 mutations are frequently found in human diseases, including myeloid leukemia, the cell proliferation-associated function of ASXL1 is largely unknown. Here, we explored the molecular mechanism underlying the growth defect found in Asxl1-deficient mouse embryonic fibroblasts (MEFs). We found that Asxl1, through amino acids 371 to 655, interacts with the kinase domain of AKT1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!